TY - JOUR
T1 - Incidence and outcomes of patients with oral cavity squamous cell Carcinoma and fourth primary tumors a long-term follow-up study in a betel quid chewing endemic area
AU - Adel, Mohamad
AU - Liao, Chun Ta
AU - Lee, Li Yu
AU - Hsueh, Chuen
AU - Lin, Chien Yu
AU - Fan, Kang Hsing
AU - Wang, Hung Ming
AU - Ng, Shu Hang
AU - Lin, Chih Hung
AU - Tsao, Chung Kan
AU - Huang, Shiang Fu
AU - Kang, Chung Jan
AU - Fang, Ku Hao
AU - Wang, Yu Chien
AU - Chang, Kai Ping
AU - Fang, Tuan Jen
AU - Yang, Lan Yan
AU - Yen, Tzu Chen
N1 - Publisher Copyright:
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016
Y1 - 2016
N2 - The aim of this study was to explore the incidence and outcomes of patients with oral cavity squamous cell carcinoma (OSCC) and fourth primary tumors (PTs) in a betel-chewing endemic area. We retrospectively examined the records of 1836 OSCC patients who underwent radical tumor resection between 1996 and 2014. The outcome measures included the incidence and number ofmultiple PTs, the main risk factors, and their associations with overall survival (OS). Of the 1836 patients, 1400 (76.3%) had a single PT, 344 (18.7%) a second PT, 67 (3.6%) a third PT, and 25 (1.4%) a fourth PT. Univariate analyses (log-rank test) identified the following factors as significantly associated with a fourth PT: simultaneous first and second PTs, betel quid chewing, buccal subsite, and pT3-4 status. After allowance for the potential confounding effect of other risk factors, all of these factors retained their independent prognostic significance in stepwise multivariate analyses, the only exception being betel chewing. The incidences of second, third, and fourth PTs at 5 and 10 years were 20.2%/34.6%, 4.0%/8.6%, and 1.0%/2.3%, respectively. The 5 and 10-year OS rates (calculated from the diagnosis of each PTs) for patients with a single, second, third, and fourth PTs were 68%/61%, 43%/37%, 45%/39%%, and 30%/30%, respectively (P<0.0001). Among patients with a fourth PT, those who underwent radical surgery showed a significantly higher 3-year OS than those who did not (57% vs 13%; P=0.0442). Fourth PTs are rarely observed in OSCC patients in a betel quidchewing endemic area. Long-term survival rates of patients treated with radical surgery seems acceptable, being 4-fold higher than their counterparts.
AB - The aim of this study was to explore the incidence and outcomes of patients with oral cavity squamous cell carcinoma (OSCC) and fourth primary tumors (PTs) in a betel-chewing endemic area. We retrospectively examined the records of 1836 OSCC patients who underwent radical tumor resection between 1996 and 2014. The outcome measures included the incidence and number ofmultiple PTs, the main risk factors, and their associations with overall survival (OS). Of the 1836 patients, 1400 (76.3%) had a single PT, 344 (18.7%) a second PT, 67 (3.6%) a third PT, and 25 (1.4%) a fourth PT. Univariate analyses (log-rank test) identified the following factors as significantly associated with a fourth PT: simultaneous first and second PTs, betel quid chewing, buccal subsite, and pT3-4 status. After allowance for the potential confounding effect of other risk factors, all of these factors retained their independent prognostic significance in stepwise multivariate analyses, the only exception being betel chewing. The incidences of second, third, and fourth PTs at 5 and 10 years were 20.2%/34.6%, 4.0%/8.6%, and 1.0%/2.3%, respectively. The 5 and 10-year OS rates (calculated from the diagnosis of each PTs) for patients with a single, second, third, and fourth PTs were 68%/61%, 43%/37%, 45%/39%%, and 30%/30%, respectively (P<0.0001). Among patients with a fourth PT, those who underwent radical surgery showed a significantly higher 3-year OS than those who did not (57% vs 13%; P=0.0442). Fourth PTs are rarely observed in OSCC patients in a betel quidchewing endemic area. Long-term survival rates of patients treated with radical surgery seems acceptable, being 4-fold higher than their counterparts.
UR - http://www.scopus.com/inward/record.url?scp=84962195667&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000002950
DO - 10.1097/MD.0000000000002950
M3 - 文章
C2 - 27015170
AN - SCOPUS:84962195667
SN - 0025-7974
VL - 95
JO - Medicine (United States)
JF - Medicine (United States)
IS - 12
M1 - e2950
ER -